MAP2K7 and neoplasm: In this work, we demonstrated that the MEK inhibitor Trametinib, as single agent, significantly reduced the proliferation and the tumor growth in two K-RAS mutated BTC models and is able to contrast the tumor growth in K-RAS WT model in association with Panitumumab.